Drug interactions and smoking: Raising awareness for acute and critical care providers

Critical Care Nursing Clinics of North America

Volumn 18, Issue 1, 2006, Pages 53-62

  Kroon, Lisa A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; NARCOTIC ANALGESIC AGENT; PSYCHOTROPIC AGENT; THEOPHYLLINE;

ACUTE DISEASE; DRUG INTERACTION; DRUG MONITORING; DRUG RESISTANCE; HUMAN; INTENSIVE CARE; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NURSE ATTITUDE; NURSING ASSESSMENT; PREVALENCE; REVIEW; SMOKING; UNITED STATES;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANALGESICS, OPIOID; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; CAFFEINE; CRITICAL CARE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE; HUMANS; LIVER; METABOLIC CLEARANCE RATE; NURSE'S ROLE; NURSING ASSESSMENT; PREVALENCE; PSYCHOTROPIC DRUGS; SMOKING; THEOPHYLLINE; UNITED STATES;

EID: 33645006402     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccell.2005.11.007     Document Type: Review

References (71)

1. National Cancer Institute Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and tobacco control monograph no. 13 October 2001 US Department of Health and Human Services, Public Health Services, National Institutes of Health, National Cancer Institute, NIH Publication # 02-5074 Bethesda, MD
2. S. Zevin, and N.L. Benowitz Drug interactions with tobacco smoking. An update Clin Pharmacokinet 36 6 1999 425 438
3. D. Hoffmann, M.V. Djordjevic, and I. Hoffmann The changing cigarette Prev Med 26 4 1997 427 434
4. Centers for Disease Control and Prevention Cigarette smoking among adults-United States, 2004 MMWR Morb Mortal Wkly Rep 54 44 2004 1121 1124
5. M.S. Faber, and U. Fuhr Time response of cytochrome P450 1A2 activity on cessation of heavy smoking Clin Pharmacol Ther 76 2 2004 178 184
6. B.L. Lee, N.L. Benowitz, and P. Jacob III Cigarette abstinence, nicotine gum, and theophylline disposition Ann Intern Med 106 4 1987 553 555
7. M.A. Eldon, P.W. Luecker, and J. MacGee Lack of effect of withdrawal from cigarette smoking on theophylline pharmacokinetics J Clin Pharmacol 27 3 1987 221 225
8. P. Mayo Effect of passive smoking on theophylline clearance in children Ther Drug Monit 23 5 2001 503 505
9. V. Ozdemir, W. Kalow, and P. Posner CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia J Clin Psychopharmacol 21 4 2001 398 407
10. J. de Leon, F.J. Diaz, and T. Rogers A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers Prog Neuropsychopharmacol Biol Psychiatry 27 1 2003 165 171
11. J. de Leon Atypical antipsychotic dosing: the effect of smoking and caffeine Psychiatr Serv 55 5 2004 491 493
12. F.J. Diaz, J. de Leon, and R.C. Josiassen Plasma clozapine concentration coefficients of variation in a long-term study Schizophr Res 72 2-3 2005 131 135
13. C. Haring, U. Meise, and C. Humpel Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age Psychopharmacology (Berl) 99 Suppl 1989 S38 S40
14. M. Gex-Fabry, A.E. Balant-Gorgia, and L.P. Balant Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication Ther Drug Monit 25 1 2003 46 53
15. J.A. Carrillo, A.G. Herraiz, and S.I. Ramos Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine J Clin Psychopharmacol 23 2 2003 119 127
16. B. Fulton, and K.L. Goa Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses Drugs 53 2 1997 281 298
17. K. Shimoda, S. Morita, and A. Yokono CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients Ther Drug Monit 22 4 2000 392 396
18. L. Pan, R. Vander Stichele, and M.T. Rosseel Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients Ther Drug Monit 21 5 1999 489 497
19. K. Shimoda, T. Someya, and S. Morita Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients Ther Drug Monit 21 3 1999 293 296
20. P.J. Perry, D.D. Miller, and S.V. Arndt Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics J Clin Psychopharmacol 13 1 1993 46 51
21. M.W. Jann, S.R. Saklad, and L. Ereshefsky Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance Psychopharmacology (Berl) 90 4 1986 468 470
22. K. Ohara, S. Tanabu, and K. Yoshida Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio Prog Neuropsychopharmacol Biol Psychiatry 27 6 2003 945 949
23. E.J. Pantuck, C.B. Pantuck, and K.E. Anderson Cigarette smoking and chlorpromazine disposition and actions Clin Pharmacol Ther 31 4 1982 533 538
24. G.L. Stimmel, and I.R. Falloon Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report J Clin Psychiatry 44 11 1983 420 422
25. O. Spigset, L. Carleborg, and K. Hedenmalm Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans Clin Pharmacol Ther 58 4 1995 399 403
26. G. Gerstenberg, T. Aoshima, and T. Fukasawa Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients Ther Drug Monit 25 4 2003 463 468
27. Xanax [package insert] December 2001 Pharmacia & Upjohn Co Kalamazoo, MI
28. K. Otani, N. Yasui, and S. Kaneko Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam Neuropsychopharmacology 16 1 1997 8 14
29. Niravam [package insert] January 2005 Schwarz Pharma Milwaukee, WI
30. R.B. Smith, P.R. Gwilt, and C.E. Wright III Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men Clin Pharm 2 2 1983 139 143
31. J.C. Fleishaker, and L.K. Hulst A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine Eur J Clin Pharmacol 46 1 1994 35 39
32. Cognex [package insert] September 1998 Parke-Davis Ann Arbor, MI
33. C. Funck-Brentano, L. Becquemont, and H.K. Kroemer Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone Clin Pharmacol Ther 55 3 1994 256 269
34. R.L. Woosley, and C. Funck-Brentano Overview of the clinical pharmacology of antiarrhythmic drugs Am J Cardiol 61 2 1988 61A 69A
35. J.L. Holtzman, C.E. Weeks, and D.C. Kvam Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate Clin Pharmacol Ther 46 1 1989 1 8
36. J.R. Schein Cigarette smoking and clinically significant drug interactions Ann Pharmacother 29 11 1995 1139 1148
37. L. Labbe, and J. Turgeon Clinical pharmacokinetics of mexiletine Clin Pharmacokinet 37 5 1999 361 384
38. M. Nakajima, K. Kobayashi, and N. Shimada Involvement of CYP1A2 in mexiletine metabolism Br J Clin Pharmacol 46 1 1998 55 62
39. O. Grech-Belanger, M. Gilbert, and J. Turgeon Effect of cigarette smoking on mexiletine kinetics Clin Pharmacol Ther 37 6 1985 638 643
40. P.M. Huet, and J. Lelorier Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics Clin Pharmacol Ther 28 2 1980 208 215
41. A.K. Wittkowsky Drug interactions update: drugs, herbs, and oral anticoagulation J Thromb Thrombolysis 12 1 2001 67 71
42. D.R. Mungall, T.M. Ludden, and J. Marshall Population pharmacokinetics of racemic warfarin in adult patients J Pharmacokinet Biopharm 13 3 1985 213 227
43. K. Bachmann, R. Shapiro, and R. Fulton Smoking and warfarin disposition Clin Pharmacol Ther 25 3 1979 309 315
44. V.J. Colucci, and J.F. Knapp Increase in international normalized ratio associated with smoking cessation Ann Pharmacother 35 3 2001 385 386
45. B. Weiner, P.A. Faraci, and R. Fayad Warfarin dosage following prosthetic valve replacement: effect of smoking history Drug Intell Clin Pharm 18 11 1984 904 906
46. R.J. Cipolle, R.D. Seifert, and B.A. Neilan Heparin kinetics: variables related to disposition and dosage Clin Pharmacol Ther 29 3 1981 387 393
47. J. Hukkanen, P. Jacob III, and N.L. Benowitz Metabolism and disposition kinetics of nicotine Pharmacol Rev 57 1 2005 79 115
48. N.L. Benowitz The role of nicotine in smoking-related cardiovascular disease Prev Med 26 4 1997 412 417
49. N.L. Benowitz, and S.G. Gourlay Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy J Am Coll Cardiol 29 7 1997 1422 1431
50. K.A. Perkins, C. Lerman, and J. Keenan Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers Nicotine Tob Res 6 3 2004 501 507
51. S. Madsbad, P. McNair, and M.S. Christensen Influence of smoking on insulin requirement and metabolic status in diabetes mellitus Diabetes Care 3 1 1980 41 43
52. P. Klemp, B. Staberg, and S. Madsbad Smoking reduces insulin absorption from subcutaneous tissue BMJ 284 6311 1982 237
53. Boston Collaborative Drug Surveillance Program Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age N Engl J Med 288 6 1973 277 280
54. H.R. Ochs, D.J. Greenblatt, and M. Knuchel Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers Chest 87 2 1985 223 226
55. T. Walle, U.K. Walle, and T.D. Cowart Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites J Pharmacol Exp Ther 241 3 1987 928 933
56. F.M. Creekmore, R.A. Lugo, and K.J. Weiland Postoperative opiate analgesia requirements of smokers and nonsmokers Ann Pharmacother 38 6 2004 949 953
57. R. Burkman, J.J. Schlesselman, and M. Zieman Safety concerns and health benefits associated with oral contraception Am J Obstet Gynecol 190 4 Suppl 2004 S5 S22
58. C. Seibert, E. Barbouche, and J. Fagan Prescribing oral contraceptives for women older than 35 years of age Ann Intern Med 138 1 2003 54 64
59. D.B. Petitti Clinical practice. Combination estrogen-progestin oral contraceptives N Engl J Med 349 15 2003 1443 1450
60. L. Chasan-Taber, and M.J. Stampfer Epidemiology of oral contraceptives and cardiovascular disease Ann Intern Med 128 6 1998 467 477
61. P.J. Schwingl, H.W. Ory, and C.M. Visness Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States Am J Obstet Gynecol 180 1 Pt 1 1999 241 249
62. L. Rosenberg, J.R. Palmer, and R.S. Rao Low-dose oral contraceptive use and the risk of myocardial infarction Arch Intern Med 161 8 2001 1065 1070
63. S. Siritho, A.G. Thrift, and J.J. McNeil Risk of ischemic stroke among users of the oral contraceptive pill: the Melbourne Risk Factor Study (MERFS) Group Stroke 34 7 2003 1575 1580
64. I. Schiff Use of oral contraceptives by women who smoke Am J Obstet Gynecol 180 6 Pt 2 1999 S341 S342
65. World Health Organization Low dose combined oral contraceptives Medical eligibility criteria for contraceptive use 3rd edition 2004 World Health Organization Geneva (Switzerland) 1 24 Available at: http://www.who.int/ reproductive-health/publications/mec/mec.pdf
66. L.A. Heinemann, A. Assmann, and T. DoMinh Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women Eur J Contracept Reprod Health Care 4 2 1999 67 73
67. R.A. Hatcher, and S. Schnare Ask the experts: progestin-only contraceptives Contracept Technol Update 14 7 1993 114 115
68. J.E. Tomlinson, A.D. McMahon, and R. Chaudhuri Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma Thorax 60 4 2005 282 287
69. G.W. Chalmers, K.J. Macleod, and S.A. Little Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma Thorax 57 3 2002 226 230
70. R. Chaudhuri, E. Livingston, and A.D. McMahon Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma Am J Respir Crit Care Med 168 11 2003 1308 1311
71. N.C. Thomson, and M. Spears The influence of smoking on the treatment response in patients with asthma Curr Opin Allergy Clin Immunol 5 1 2005 57 63